Abstract
Objectives
Diabetes can lead to loss of protective sensation (LOPS) in the feet. Identifying
LOPS requires use of screening tests, such as the standard monofilament test (SMT)
and the Ipswich Touch Test (IpTT). The aim of this validation study was to compare
the SMT (criterion) with the IpTT (new test).
Methods
Each participant was randomly tested using the SMT, IpTT and Neuropathy Disability
Score to identify LOPS. Sixteen health-care providers assessed 8 participants in randomized
order using a specific protocol.
Results
The IpTT, compared with the SMT, demonstrated a specificity of 100% for all raters
and a mean sensitivity of 93.8% for LOPS. Kappa coefficient was 0.97 for SMT and 0.83
for IpTT.
Conclusions
The IpTT can be used by health-care providers as an effective tool for screening for
LOPS in people with diabetes. This study validated the IpTT to the SMT in identifying
LOPS.
Résumé
Objectifs
Le diabète peut entraîner la perte de sensibilité protectrice (PDSP) dans les pieds.
Le dépistage de la PDSP exige l’utilisation de tests de dépistage tels que le test
standard au monofilament (TSM) et l’Ispwich Touch Test (IpTT). L’objectif de la présente étude de validation visait à comparer le TSM (critère)
à l’IpTT (nouveau test).
Méthodes
Chaque participant a été soumis de façon aléatoire au TSM, à l’IpTT et au Neuropathy Disability Score pour dépister la PDSP. Seize prestataires de soins de santé ont évalué 8 participants
dans un ordre aléatoire suivant un protocole particulier.
Résultats
Comparativement au TSM, l’IpTT a démontré une spécificité de 100 % pour tous les évaluateurs
et une sensibilité moyenne de 93,8 % pour la PDSP. Le coefficient kappa était de 0,97
pour le TSM et de 0,83 pour l’IpTT.
Conclusions
L’IpTT peut constituer pour les prestataires de soins de santé un outil de dépistage
efficace de la PDSP chez les personnes diabétiques. Cette étude a permis de valider
l’utilisation de l’IpTT par rapport à l’utilisation du TSM dans le dépistage de la
PDSP.
Keywords
Mots clés
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- IDF Diabetes Atlas.9th edition. 2019https://www.diabetesatlas.org/upload/resources/material/20200302_133351_idfatlas9e-final-web.pdfDate accessed: May 7, 2021
- The global burden of diabetic foot disease.Lancet. 2005; 366: 1719-1724
- Prediction of diabetic foot ulcer occurrence using commonly available clinical information: The Seattle Diabetic Foot Study.Diabetes Care. 2006; 29: 1202-1207
- Management of diabetic peripheral neuropathy.Clin Diabetes. 2005; 23: 9-15
- Foot care.Can J Diabetes. 2018; 42: S222-S227
- American Diabetes Association. Preventive foot care in diabetes.Diabetes Care. 2004; 27: S63-S64
- Defining loss of protective sensation in the diabetic foot.Adv Wound Care. 1998; 11: 123-128
- Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.Arch Intern Med. 1998; 158: 289-292
- Diabetic neuropathy: A review emphasizing diagnostics methods.Clin Neurophysiol. 2003; 114: 1167-1175
- Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update).Diabetes Metab Res Rev. 2020; 36: e3269
- Accuracy and durability of Semmes-Weinstein monofilaments: What is the useful service life?.Diabetes Res Clin Pract. 2012; 97: 399-404
- Clinical examination for the detection of protective sensation in the feet of diabetic patients.J Gen Intern Med. 1999; 14: 418-424
- A comparison of the monofilament with other testing modalities for foot ulcer susceptibility.Diabetes Res Clin Pract. 2005; 70: 8-12
- The clinical use of the 10g monofilament and its limitations: A review.Diabetes Res Clin Pract. 2010; 90: 1-7
- Sensory thresholds of normal human feet.Foot Ankle Int. 2000; 21: 501-504
- Semmes-Weinstein monofilaments: A simple, effective and inexpensive device for identifying diabetic patients at risk of foot ulceration.Diabetes Res Clin Pract. 1991; 13: 63-67
- Differences in the performance of commercially available 10-g monofilaments.Diabetes Care. 2000; 23: 984-988
- The Ipswich Touch Test: A simple and novel method to identify inpatients with diabetes at risk of foot ulceration.Diabetes Care. 2011; 34: 1517-1518
- How to do a 3-minute diabetic foot exam.J Fam Pract. 2014; 63 (Erratum in: J Fam Pract 2015;64:452): 646-656
- A pocket-sized disposable device for testing the integrity of sensation in the outpatient setting.Diabet Med. 2012; 29: 1550-1552
- Utilizing the Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration among diabetics: The Saudi experience.Prim Care Diabetes. 2015; 9: 304-306
- The Ipswich Touch Test: A simple and novel method to screen patients with diabetes at home for increased risk of foot ulceration.Diabet Med. 2014; 31: 1100-1103
- Is it possible to substitute the monofilament test for the Ipswich Touch Test in screening for peripheral diabetic neuropathy?.Diabetol Metab Syndr. 2020; 12: 27
- The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes.J Fam Pract. 2000; 49: 17-29
- The North-West Diabetes Foot Care Study: Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort.Diabet Med. 2002; 19: 377-384
- Behavior patterns of physical therapists in screening for loss of protective sensation in clients with diabetes.Hosp Top. 2013; 91: 53-58
Article Info
Publication History
Published online: August 02, 2022
Accepted:
July 19,
2022
Received in revised form:
May 25,
2022
Received:
March 16,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Canadian Diabetes Association.
